P resenting stroke severity, most commonly assessed using the National Institutes of Health Stroke Scale (NIHSS), is the single most important predictor of final outcome in ischemic stroke patients. [1] [2] [3] Accordingly, adjusting for presenting stroke deficit severity as a baseline covariate is a crucial step in the analysis of treatment trials and quality of care registries.
However, the relationship between early stroke deficits and final outcome is likely to be time-dependent. Two major potential contributing processes to time dependence can be identified: (1) In the first few hours after onset, stroke deficits are unstable, prone to sudden improvements with recanalization or sudden worsenings with clot propagation or collateral failure; whereas, beyond the first 6 to 10 hours, most of the injury has already accrued and deficits tend not to change suddenly. 4, 5 (2) In the subacute period from 12 hours to 7 days, most patients without complications experience steady modest deficit improvement, because of resolution of diaschisis and the beneficial effects of early neuroplasticity. 6 This study sought to delineate the degree to which time of measurement alters the relationship of early stroke deficit severity to final functional outcome by analyzing the serial measures available in the public data set of the 2 National Institute of Neurological Disorders and Stroke (NINDS) tissue-type plasminogen activator (tPA) treatment trials.
Methods
Analysis was performed on placebo control patients enrolled onto the 2 NINDS-tPA trials. 7 In these trials, NIHSS measures that could predict final functional outcome were obtained at 1 to 3 hours, 3 to 5 hours, 24 hours, and 7 to 10 days postonset. We used as the primary outcome measure at 90 days global disability status on the modified Rankin Scale (mRS).
The course of change in the NIHSS was assessed in 3 ways. The median NIHSS was calculated at each time point. The proportions of patients who improved or worsened on the NIHSS in the early time window between 1 to 3 hours to 24 hours were calculated, using thresholds of changing by 2 or more and 4 or more scale points. In addition, the proportion of patients who improved or worsened on the NIHSS in the early time window between 1 to 3 hours to 24 hours by normalized changes of 25% and 50% were calculated. The normalized change is the observed change divided by total possible change. 8 Following the convention in the NINDS-tPA trials, and in acute stroke trials generally, patients who had died by an evaluation time point were assigned the worst possible NIHSS, 42, at that time point. For the few patients known alive, but who were not neurologically examined at a time point, the main analysis was performed on the NIHSS scores that included the imputed values provided in the public data set. In the placebo group, there were no such patients at 1 to 3 hours, 3 to 5 hours, or 24 hours; 6 patients (1.9%) at 7 to 10 days; and 6 patients (1.9%) at 90 days. Sensitivity analysis censoring missing data showed similar findings as did the main analysis.
Associations between early course NIHSS measures and final mRS were analyzed using correlation coefficients. For comparison, the association of day-90 NIHSS with day-90 mRS was also analyzed. The association of concurrent NIHSS with mRS indicates the maximum possible explanatory value of stroke deficit severity in accounting for global disability.
To assess the impact of NIHSS score evolution on identifying patients likely to have excellent outcomes, who not be informative if enrolled in clinical trials, we identified the NIHSS thresholds that identified patients with a Ͼ75% chance of reaching a 90-day mRS score of 0 to 1, and the proportion of the population these thresholds would exclude.
Results
Evolution of the NIHSS score over time is shown in Table 1 . Among the 312 control patients, median stroke deficit severity improved throughout the 90-day observation period. For example, the median NIHSS improved from 15 (interquartile range [IQR], 9.5-20) at 1 to 3 hours, to 7 (IQR, 2-19) at 90 days. In the early time period between 1 to 3 hours to 24 hours, the proportion of patients who spontaneously improved outnumbered the proportion who spontaneously worsened. Improvements by 4 or more points occurred in 39.1% versus worsening in 17.6% (PϽ0.001). Improvements by 2 or more points occurred in 53.8% versus worsening in 23.7% (PϽ0.001). Similarly, normalized change improvements by 50% or more occurred in 20.8% versus worsening in 2.2% (PϽ0.001), and normalized change improvements by 25% or more occurred in 39.7% versus worsening in 8.0% (PϽ0.001). The distribution of the NIHSS became progressively more bimodal over time, as more patients experienced fatal outcome, with extreme assigned NIHSS score of 42, and surviving patients experienced progressive deficit improvement ( Figure 1 ).
The correlation between the NIHSS and the final mRS increased over the 90-day period ( Table 1 ). The 1-to-3-hourpostonset NIHSS accounted for 28% of the variance in final disability outcome, the 24-hour NIHSS 52%, and the day-90 NIHSS 76%.
In a subgroup analysis, the control cohort was split between patients who had their baseline NIHSS measured within the first 90 minutes (nϭ156) and patients who had their baseline NIHSS measured between 91 to 180 minutes (nϭ156). The proportion of patients with early spontaneous substantial improvement (by 4 or more points) between baseline and 24 hours was nominally higher among patients with first NIHSS measured at 0 to 90 minutes than among those with first NIHSS measured at 91 to 180 minute; however, the difference did not reach statistical significance (42.4% versus 36.5%; Pϭ0.29). Similarly, the correlation coefficients for predicting final 90-day mRS were nominally lower among those with first NIHSS measured at 0 to 90 minutes (0.47 [95% CI, 0.33-0.59]), than among those with first NIHSS measured at 91 to 180 minutes (0.54 [95% CI, 0.42-0.64]), but the difference did not reach statistical significance.
A shift to lower values over time was noted in the NIHSS scores associated with individual final mRS ranks (Table 2, Figure 2 ). For example, patients with a final mRS of 2 had the following median NIHSS scores: 1 to 3 hours, 12 (IQR, 8 -16.5); 3 to 5 hours, 10 (IQR, 7-13); 24 hours, 9 (IQR, 5.5-12); 7 to 10 days, 6 (IQR, 4 -8.5); and 90 days, 3 (IQR, 2-4). Conversely, a shift to higher values was noted in the final mRS scores associated with the same NIHSS scores obtained at different time points (Table 3) .
The NIHSS values below which 75% of population were destined for an excellent final mRS outcome of 0 to 1 were 8 at 1 to 3 hours, 5 at 3 to 5 hours, 6 at 24 hours, and 5 at 7 to 10 days (versus 3 at 90 days). The proportion of the placebo population that would be excluded by these thresholds were 7.7% at 1 to 3 hours, 10.3% at 3 to 5 hours, 21.8% at 24 hours, and 28.5% at 7 to 10 days (versus 27.2% at 90 days).
Discussion
This analysis of the serial NIHSS assessments performed in the control arm of the 2 NINDS-tPA trials demonstrates 3 key findings critical for clinical trial and quality improvement activities.
First, stroke deficit severity is highly labile in the first few hours postonset. Both early improvements and early worsening occur, but early spontaneous improvement is substantially more common. Substantial spontaneous improvements during the first 24 hours occur in nearly 40% of patients, and are twice as common as is spontaneous worsening. This finding confirms and extends observations of frequent early improvement in small, single-center studies. 4, 5 Second, the prognostic value of the NIHSS score for final functional outcome improves as time from stroke onset increases. The influence of very early NIHSS measures on final outcome is attenuated when subsequent fluctuations alter patient course. As stroke deficit severity lability declines over time, the predictive power of the NIHSS grows. An NIHSS assessed in the first 3 hours after onset accounts for only one quarter of the variation in final outcome. By 24 Figure 1 . NIHSS score distributions at 1 to 3 hours, 3 to 5 hours, 24 hours, 7 to 10 days, and 90 days in the placebo arms of the 2 NINDS-tPA trials. X axis is NIHSS score and y axis is percent of patients with that score. Most patients' NIHSS scores begin shifting to lower values as early as 3 to 5 hours, continuing through 90 days. The minority of patients with fatal outcome and concomitant extremely poor NIHSS scores begin to appear after 24 hours and increase by day 90. Over time, the NIHSS median evolves from severe to moderate and the NIHSS distribution evolves from unimodal to bimodal. hours after onset, the NIHSS accounts for one half of the final outcome. The final NIHSS, measured concurrently with final global disability, accounts for fully three quarters of the final outcome. Third, a marked shift in the relationship between particular NIHSS score values and final outcome occurs over time. Given that the NIHSS typically improves in almost all patients who do not have fatal outcome, the same NIHSS score will have a worse prognosis when present later in the course. Steady reductions over time in the median NIHSS associated with final 90-day mRS ranks were seen for each of ranks 0 to 4. For example, patients destined for a final independent, but disabled, 90-day outcome (mRS 2) had an NIHSS median score of 12 at 1 to 3 hours, 10 at 3 to 5 hours, 9 at 24 hours, 6 at 1 week, and 3 at 90 days. Variations in this pattern were seen for the severe outcomes levels of mRS 5 and 6. For rank 5, associated median NIHSS scores were severe and unchanging over time. For rank 6 (mortality), the associated NIHSS scores increased over time, as an increasing proportion of patients had fatal outcome and were assigned an extreme NIHSS score of 42.
These findings have important consequences for prognostic modeling in clinical trials and quality improvement activities. Useful prognostic models almost invariably include a measure of initial stroke deficit severity as a predictor variable, as early deficit is the single most important prognostic factor in acute stroke. However, most models that have been presented in the literature have treated the relationship between initial deficit severity and final outcome as unaffected by the time of initial NIHSS assessment. [1] [2] [3] This study's findings demonstrate 2 weaknesses of such a timeinvariant approach. First, because the explanatory power of the NIHSS increases over time, the prognostic weight assigned to the NIHSS should similarly increase. Second, given that the relationship between particular NIHSS score values and final outcome shifts over time, the same score can portend very different outcomes if it was assessed at 1 to 3 hours, 3 to 5 hours, or at 24 hours. Prognostic models designed for broad populations therefore should incorporate time from stroke onset until measurement of the baseline NIHSS as an additional variable or interaction term.
Clinical trials of different therapeutic strategies typically enroll patients onto different time windows. Intravenous thrombolytic agents have been successfully trialed in the 0-to-4.5-hour window, whereas mechanical endovascular therapies have been generally studied in the 3-to-8-hour window, and neuroplasticity enhancing therapies have typically been studied in the 24-to-72-hour window. The findings from this study indicate that prognostic models derived from populations with baseline measures obtained in a particular time period should generally be applied only to populations having baseline measures assessed in similar time periods.
The time-specific correlations reported in this study can also be helpful in designing clinical trial entry criteria and win criteria. NIHSS thresholds to identify likely uninformative patients for a particular win criterion shift lower and increase in their population impact over time. For instance, for the win criterion of a nondisabled outcome (mRS 0 -1) at 90 days, patients very likely to be uninformative because of high rates of win outcomes in the placebo group would be those with NIHSS scores of 8 at 1 to 3 hours, versus 6 at 24 hours; the 1-to-3-hour cutoff would exclude Ͻ10% of NINDS-study-like patients, but the 24-hour cutoff would exclude 22%.
This study has limitations. The 2 NINDS trial control cohorts were enrolled in the early 1990s. Supportive care practices have evolved in several subtle ways in the subsequent decade-and-a-half, and the serial course of current patients may be mildly different. This study examined only the NIHSS, and not other measures of stroke deficit severity. However, the NIHSS is the most widely employed formal assessment in clinical trials and in clinical practice worldwide. The data set analyzed was modest in size and did not have data on all time points of interest (eg, 6 hours, 12 hours). Confirmation and extension of our findings in larger and more varied databases is needed.
Conclusions
In conclusion, serial stroke deficit severity measurement in supportively treated patients demonstrates that spontaneous early improvement is common in acute ischemic stroke, severity of stroke deficits becomes increasingly determinative of final outcome over time, and the same deficit severity score is associated with worse outcome when present later in a patient's course. Accordingly, time from onset to initial measurement of stroke deficit severity is an important candidate variable for inclusion in prognostic outcome models.
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